Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 2 trial found that patients with locally advanced head and neck cancer who responded well to neoadjuvant immunochemotherapy could safely undergo less extensive surgery — with impressive results. Those who had reduced-volume surgery achieved a 2-year disease-free survival of 90% and 100% laryngeal preservation, compared to just 20% survival in patients who needed standard surgery.
A phase 2 trial called REMATCH is offering new hope for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) — a cancer notorious for its aggressive treatment and high recurrence rates. The trial tested whether patients who respond well to neoadjuvant immunochemotherapy (ICT) could safely undergo reduced-volume surgery instead of the standard radical approach, potentially sparing them from significant long-term side effects.
The results were striking. Among 50 patients evaluated, 94% responded to ICT and 90% achieved more than 50% tumor shrinkage — qualifying them for the less extensive surgery. Those who underwent reduced-volume surgery had dramatically better outcomes than those who required standard surgery.
Why it matters: These findings suggest that tailoring surgical extent to a patient's treatment response could dramatically improve survival and quality of life — preserving the voice box and reducing toxicity. Researchers are now calling for phase 3 randomized trials to confirm this de-escalation strategy.
